saralasin
Trade name: sarenin
Small moleculeapproved
Saralasin is an angiotensin II analogue which was developed for the treatment of hypertension in 1970s. For many years saralasin was supposed to be angiotensin receptors blocker, but recent studies have revealed that its pharmacological action can be explained by agonistic behavior toward angiotensin II receptor. The drug was approved by FDA under the name Sarenin, however, it is no longer available on the market. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1970s
- Jun 1, 1979
Norwich Eaton Company — First NDA Organization
- Jun 1, 1979
Norwich Eaton Company — NDA Organization
Indications
Approved for
Mechanism of action
- Type-1 angiotensin II receptorANTAGONIST
AGTR1 antagonist
Approval history
- approved—
Chemistry & pharmacology
Loading structure…
SMILES
CNCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C- Mol. weight
- 912.06 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL938 ↗
- WikipediaSaralasin ↗
- NCATSH2AFV2HE66 ↗
- ChEMBLCHEMBL1200670 ↗
Also known as
- aralasin
- p-113
- p-113
- saralasin
- saralasin
- saralasin
- saralasin
- saralasin
- saralasin
- saralasin acetate
- saralasin acetate
- saralasin acetate
- saralasin acetate
- saralasin acetate
- saralasin acetate
- saralasin acetate hydrate
- sarenin
- sarenin
- sarenin
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Norwich Eaton Company | For profit | NDA | Jun 1, 1979 |
| Procter and Gamble | For profit | NDA2 | — |